Artelo Biosciences, Inc. (ARTL)
NASDAQ: ARTL · Real-Time Price · USD
6.79
-0.07 (-1.02%)
At close: Jun 27, 2025, 4:00 PM
6.82
+0.03 (0.44%)
After-hours: Jun 27, 2025, 7:31 PM EDT

Artelo Biosciences Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2021 2016 - 2020
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Aug '21 2016 - 2020
Selling, General & Admin
4.034.124.235.966.294.6
Upgrade
Research & Development
5.875.995.74.325.832.84
Upgrade
Operating Expenses
9.910.119.9310.2912.137.44
Upgrade
Operating Income
-9.9-10.11-9.93-10.29-12.13-7.44
Upgrade
Interest Expense
----0.01--
Upgrade
Interest & Investment Income
0.01--000
Upgrade
EBT Excluding Unusual Items
-9.89-10.11-9.93-10.29-12.12-7.44
Upgrade
Gain (Loss) on Sale of Investments
0.180.280.640.210.020
Upgrade
Pretax Income
-9.72-9.83-9.29-10.08-12.11-7.44
Upgrade
Net Income
-9.72-9.83-9.29-10.08-12.11-7.44
Upgrade
Net Income to Common
-9.72-9.83-9.29-10.08-12.11-7.44
Upgrade
Shares Outstanding (Basic)
110000
Upgrade
Shares Outstanding (Diluted)
110000
Upgrade
Shares Change (YoY)
6.53%8.88%4.48%27.04%79.12%403.69%
Upgrade
EPS (Basic)
-17.97-18.29-18.83-21.35-32.57-35.84
Upgrade
EPS (Diluted)
-17.97-18.29-18.83-21.35-32.58-35.84
Upgrade
Free Cash Flow
-7.01-8.35-8.21-8.01-8-6.14
Upgrade
Free Cash Flow Per Share
-12.96-15.54-16.64-16.96-21.53-29.59
Upgrade
EBITDA
------7.44
Upgrade
D&A For EBITDA
-----0
Upgrade
EBIT
-9.9-10.11-9.93-10.29-12.13-7.44
Upgrade
Updated Mar 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q